BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 21434883)

  • 1. Inhibition of the signalling kinase JAK3 alleviates inflammation in monoarthritic rats.
    Kim BH; Kim M; Yin CH; Jee JG; Sandoval C; Lee H; Bach EA; Hahm DH; Baeg GH
    Br J Pharmacol; 2011 Sep; 164(1):106-18. PubMed ID: 21434883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NSC114792, a novel small molecule identified through structure-based computational database screening, selectively inhibits JAK3.
    Kim BH; Jee JG; Yin CH; Sandoval C; Jayabose S; Kitamura D; Bach EA; Baeg GH
    Mol Cancer; 2010 Feb; 9():36. PubMed ID: 20149240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MS-1020 is a novel small molecule that selectively inhibits JAK3 activity.
    Kim BH; Oh SR; Yin CH; Lee S; Kim EA; Kim MS; Sandoval C; Jayabose S; Bach EA; Lee HK; Baeg GH
    Br J Haematol; 2010 Jan; 148(1):132-43. PubMed ID: 19793252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease.
    Mahajan S; Hogan JK; Shlyakhter D; Oh L; Salituro FG; Farmer L; Hoock TC
    J Pharmacol Exp Ther; 2015 May; 353(2):405-14. PubMed ID: 25762693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors.
    Haan C; Rolvering C; Raulf F; Kapp M; Drückes P; Thoma G; Behrmann I; Zerwes HG
    Chem Biol; 2011 Mar; 18(3):314-23. PubMed ID: 21439476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a high-throughput cell-based reporter assay for screening of JAK3 inhibitors.
    Yin CH; Bach EA; Baeg GH
    J Biomol Screen; 2011 Apr; 16(4):443-9. PubMed ID: 21393628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tubulosine selectively inhibits JAK3 signalling by binding to the ATP-binding site of the kinase of JAK3.
    Kim BH; Yi EH; Jee JG; Jeong AJ; Sandoval C; Park IC; Baeg GH; Ye SK
    J Cell Mol Med; 2020 Jul; 24(13):7427-7438. PubMed ID: 32558259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 Inhibitor.
    Elwood F; Witter DJ; Piesvaux J; Kraybill B; Bays N; Alpert C; Goldenblatt P; Qu Y; Ivanovska I; Lee HH; Chiu CS; Tang H; Scott ME; Deshmukh SV; Zielstorff M; Byford A; Chakravarthy K; Dorosh L; Rivkin A; Klappenbach J; Pan BS; Kariv I; Dinsmore C; Slipetz D; Dandliker PJ
    J Pharmacol Exp Ther; 2017 May; 361(2):229-244. PubMed ID: 28193636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J mice.
    Chang BY; Zhao F; He X; Ren H; Braselmann S; Taylor V; Wicks J; Payan DG; Grossbard EB; Pine PR; Bullard DC
    J Immunol; 2009 Aug; 183(3):2183-92. PubMed ID: 19596999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tofacitinib ameliorates inflammation in a rat model of airway neutrophilia induced by inhaled LPS.
    Calama E; Ramis I; Domènech A; Carreño C; De Alba J; Prats N; Miralpeix M
    Pulm Pharmacol Ther; 2017 Apr; 43():60-67. PubMed ID: 28087469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel 1H-pyrazolo[3,4-d]pyrimidin-6-amino derivatives as potent selective Janus kinase 3 (JAK3) inhibitors. Evaluation of their improved effect for the treatment of rheumatoid arthritis.
    Yin Y; Chen CJ; Yu RN; Shu L; Wang ZJ; Zhang TT; Zhang DY
    Bioorg Chem; 2020 May; 98():103720. PubMed ID: 32171982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of tricyclic JAK3 inhibitors with picomolar affinities as novel molecular probes.
    Gehringer M; Pfaffenrot E; Bauer S; Laufer SA
    ChemMedChem; 2014 Feb; 9(2):277-81. PubMed ID: 24403205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a highly selective JAK3 inhibitor for the treatment of rheumatoid arthritis.
    Pei H; He L; Shao M; Yang Z; Ran Y; Li D; Zhou Y; Tang M; Wang T; Gong Y; Chen X; Yang S; Xiang M; Chen L
    Sci Rep; 2018 Mar; 8(1):5273. PubMed ID: 29588471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tricyclic covalent inhibitors selectively target Jak3 through an active site thiol.
    Goedken ER; Argiriadi MA; Banach DL; Fiamengo BA; Foley SE; Frank KE; George JS; Harris CM; Hobson AD; Ihle DC; Marcotte D; Merta PJ; Michalak ME; Murdock SE; Tomlinson MJ; Voss JW
    J Biol Chem; 2015 Feb; 290(8):4573-4589. PubMed ID: 25552479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma.
    Sibbesen NA; Kopp KL; Litvinov IV; Jønson L; Willerslev-Olsen A; Fredholm S; Petersen DL; Nastasi C; Krejsgaard T; Lindahl LM; Gniadecki R; Mongan NP; Sasseville D; Wasik MA; Iversen L; Bonefeld CM; Geisler C; Woetmann A; Odum N
    Oncotarget; 2015 Aug; 6(24):20555-69. PubMed ID: 26244872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective inhibitors of the Janus kinase Jak3--Are they effective?
    Thoma G; Drückes P; Zerwes HG
    Bioorg Med Chem Lett; 2014 Oct; 24(19):4617-4621. PubMed ID: 25217444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition.
    Telliez JB; Dowty ME; Wang L; Jussif J; Lin T; Li L; Moy E; Balbo P; Li W; Zhao Y; Crouse K; Dickinson C; Symanowicz P; Hegen M; Banker ME; Vincent F; Unwalla R; Liang S; Gilbert AM; Brown MF; Hayward M; Montgomery J; Yang X; Bauman J; Trujillo JI; Casimiro-Garcia A; Vajdos FF; Leung L; Geoghegan KF; Quazi A; Xuan D; Jones L; Hett E; Wright K; Clark JD; Thorarensen A
    ACS Chem Biol; 2016 Dec; 11(12):3442-3451. PubMed ID: 27791347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.
    Losdyck E; Hornakova T; Springuel L; Degryse S; Gielen O; Cools J; Constantinescu SN; Flex E; Tartaglia M; Renauld JC; Knoops L
    J Biol Chem; 2015 Nov; 290(48):29022-34. PubMed ID: 26446793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A receptor-independent, cell-based JAK activation assay for screening for JAK3-specific inhibitors.
    Oh K; Joo KM; Jung YS; Lee J; Kang H; Lee HY; Lee DS
    J Immunol Methods; 2010 Mar; 354(1-2):45-52. PubMed ID: 20138049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uncoupling JAK3 activation induces apoptosis in human lymphoid cancer cells via regulating critical survival pathways.
    Nagy ZS; Ross JA; Rodriguez G; Bader J; Dimmock J; Kirken RA
    FEBS Lett; 2010 Apr; 584(8):1515-20. PubMed ID: 20211620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.